Table 6 Activity of bortezomib in multiple myeloma

Retrospective study

Min et al. , 2007

1.3 mg/m² twice

Yes

2-4

21

12.1

NR

NR

[15]

weekly for 2

weeks in a 21-day

cycle

Corso A, et al.

1.3 mg/m² on days

Yes

≥ 2

61

5.6

5.4

14.6

2009

1, 4, 8, and 11 of a

[16]

21-day cycle

Ohguchi H, et al.

1.3 mg/m²on days

Yes

≥ 2

40

8.7

NR

NR

2009

1, 4, 8, and 11 of a

[17]

21-day cycle

Present study

1.3 mg/m² on days

Yes

1-9

44

14.9

14.9

38.3

1, 4, 8, and 11 of a

21-day cycle

or

1.3 mg/m² intravenously

1, 8, 15, and 22 of every

35-day cycle

Phase II

Richardson et al. 2003

1.3 mg/m² on days

Yes

≥ 2

202

7.0

NR

16.0

[12]

1, 4, 8, and 11 of a

21-day cycle

Jagannath et al. 2004

1.3 mg/m²twice

Yes

2-8

26

11.0

NR

NR

[13]

for 2 weeks in a

21-day

Richardson PG, et al.

1.3 mg/m² on days

No

1

64

17.3

17.0

NR

2009

1, 4, 8, and 11 of a

[18]

21-day cycle

Phase III

Kane et al. 2006

1.3 mg/m² on days

Yes

≥ 2

333

6.2

5.7

NR

[19]

1, 4, 8, and 11 of a

21-day cycle

(4 doses) for up to

8 cycles, followed by

up to 3 additional

5-week cycles of once

weekly dosing

(4 doses)

Orlowskiet al. 2007

1.3 mg/m2 on days

No

≥ 2

322

6.5

6.5

NR

[20]

1, 4, 8, and 11 of a

21-day cycle

Richardson et al., 2007

1.3 mg/m2 on days

No

2-4

333

1.4

NR

29.8

[21]

1, 4, 8, and 11

for eight 3-week

cycles, then on days

1, 8, 15, and 22 for

three 5-week

maintenance

cycles

Sonneveld P, et al.

1.3 mg/m2 on days

No

≥ 2

184

6.8

NR

NR

2008

1, 4, 8, and 11 of a

[22]

21-day cycle